SHANGHAI, Feb. 4, 2023 /PRNewswire/ -- Qiming Venture Partners' portfolio company Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical stage global biopharmaceutical company focusing on novel oral small molecule therapeutics, successfully debuts on Nasdaq on February 3 Beijing Time. It issued at $15.00 per ADS, opened at $25.00 per ADS and up by 66.67%, representing a market cap of $915 million.
Read more at prnewswire.comhello world
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
